CN102861097B - Application of Houttuynoid E in medicine for treating bladder cancer - Google Patents
Application of Houttuynoid E in medicine for treating bladder cancer Download PDFInfo
- Publication number
- CN102861097B CN102861097B CN 201210418823 CN201210418823A CN102861097B CN 102861097 B CN102861097 B CN 102861097B CN 201210418823 CN201210418823 CN 201210418823 CN 201210418823 A CN201210418823 A CN 201210418823A CN 102861097 B CN102861097 B CN 102861097B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- bladder cancer
- medicine
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid E in preparation of a medicine for treating bladder cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid E has the remarkable inhibitory effects on the growth of human bladder cancer cell strain T-24 through the evaluation of in vitro MTT antineoplastic activity. Therefore, Houttuynoid E can be used for preparing the anti-bladder cancer medicine and has good development and application prospects. The application of Houttuynoid E in preparation of the medicine for treating bladder cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid E on bladder cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid E, relate in particular to the application of Houttuynoid E in preparing the anti-bladder cancer medicine.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be the natural product or derivatives thereof, as paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, searching anticancer compound or lead compound have great importance.
The compound H outtuynoid E the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid E the present invention relates in preparation treatment bladder cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for transitional cell bladder carcinoma cell line is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for bladder cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid E in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid E in preparing the anti-bladder cancer medicine, and the structural formula of Houttuynoid E is as shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid E also has significant inhibitory action to the growth of human bladder cancer cell's strain T-24, suppresses the IC of this 1 strain Growth of Cells
50value is respectively 0.30 ± 0.04 μ M.Therefore, Houttuynoid E can, for the preparation of the anti-bladder cancer medicine, have good development prospect.
The purposes of the Houttuynoid E the present invention relates in preparation treatment bladder cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for transitional cell bladder carcinoma cell line is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for bladder cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid E to human bladder cancer cell's strain
1. method: in the cell of growth logarithmic (log) phase: human bladder cancer cell's strain T-24(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4the concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that the drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid E of 0.0001 μ M and 0.00001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Houttuynoid E has significant inhibitory action to the growth of human bladder cancer cell's strain T-24.This compound suppresses the IC of human bladder cancer cell's strain T-24 growth
50value is: 0.30 ± 0.04 μ M.
By above-described embodiment, shown, Houttuynoid E of the present invention has good inhibitory action to the growth of human bladder cancer cell's strain T-24.Prove thus, Houttuynoid E of the present invention has the anti-bladder cancer activity, can be for the preparation of the anti-bladder cancer medicine.
Claims (1)
1.Houttuynoid the application of E in preparation treatment bladder cancer medicine, described compound H outtuynoid E structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210418823 CN102861097B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating bladder cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210418823 CN102861097B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861097A CN102861097A (en) | 2013-01-09 |
| CN102861097B true CN102861097B (en) | 2013-12-18 |
Family
ID=47440415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210418823 Expired - Fee Related CN102861097B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in medicine for treating bladder cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861097B (en) |
-
2012
- 2012-10-27 CN CN 201210418823 patent/CN102861097B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| Houttuynoids A_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen 等;《Organic Letters》;20120313;第14卷(第07期);第1772–1775页 * |
| Shao-DanChen等.HouttuynoidsA_E Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012 |
| 石曾敏 等.自拟益气化结汤***经验.《实用中医内科杂志》.1995,第09卷(第01期),第16页. |
| 自拟益气化结汤***经验;石曾敏 等;《实用中医内科杂志》;19950325;第09卷(第01期);第16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861097A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861073B (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102861094B (en) | Application of Houttuynoid E in medicine for treating bile duct cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102861071B (en) | Application of Houttuynoid A in medicine for treating gastric cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer | |
| CN102872135A (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU KANGHENG CHEMICAL CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141127 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226500 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141127 Address after: 226500, Jiangsu, Rugao town (Rugao port area) 8 West Hong Kong Road (Fine Chemical Industry Park) Patentee after: Jiangsu Kangheng Chemical Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131218 Termination date: 20191027 |